<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26791720</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>04</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1476-4687</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>529</Volume>
            <Issue>7586</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>Jan</Month>
              <Day>21</Day>
            </PubDate>
          </JournalIssue>
          <Title>Nature</Title>
          <ISOAbbreviation>Nature</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Metastatic colonization by circulating tumour cells.</ArticleTitle>
        <Pagination>
          <StartPage>298</StartPage>
          <EndPage>306</EndPage>
          <MedlinePgn>298-306</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/nature17038</ELocationID>
        <Abstract>
          <AbstractText>Metastasis is the main cause of death in people with cancer. To colonize distant organs, circulating tumour cells must overcome many obstacles through mechanisms that we are only now starting to understand. These include infiltrating distant tissue, evading immune defences, adapting to supportive niches, surviving as latent tumour-initiating seeds and eventually breaking out to replace the host tissue. They make metastasis a highly inefficient process. However, once metastases have been established, current treatments frequently fail to provide durable responses. An improved understanding of the mechanistic determinants of such colonization is needed to better prevent and treat metastatic cancer.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Massagué</LastName>
            <ForeName>Joan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York 10065, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Obenauf</LastName>
            <ForeName>Anna C</ForeName>
            <Initials>AC</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York 10065, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Research Institute of Molecular Pathology, Vienna Biocenter, 1030 Vienna, Austria.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>CA163167</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P30 CA008748</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U54 CA163167</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>CA129243</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P01 CA129243</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Nature</MedlineTA>
        <NlmUniqueID>0410462</NlmUniqueID>
        <ISSNLinking>0028-0836</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009360" MajorTopicYN="N">Neoplastic Cells, Circulating</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009928" MajorTopicYN="N">Organ Specificity</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055153" MajorTopicYN="N">Stem Cell Niche</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2015</Year>
          <Month>8</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2015</Year>
          <Month>11</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>1</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>1</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>4</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26791720</ArticleId>
        <ArticleId IdType="mid">NIHMS816822</ArticleId>
        <ArticleId IdType="pmc">PMC5029466</ArticleId>
        <ArticleId IdType="doi">10.1038/nature17038</ArticleId>
        <ArticleId IdType="pii">nature17038</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Nagrath S, et al.  Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007;450:1235–1239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3090667</ArticleId>
            <ArticleId IdType="pubmed">18097410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Braun S, et al.  A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005;353:793–802.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16120859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong CW, et al.  Apoptosis: an early event in metastatic inefficiency. Cancer Res. 2001;61:333–338.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11196183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Minn AJ, et al.  Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest. 2005;115:44–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC539194</ArticleId>
            <ArticleId IdType="pubmed">15630443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2:563–572.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12154349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luzzi KJ, et al.  Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol. 1998;153:865–873.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1853000</ArticleId>
            <ArticleId IdType="pubmed">9736035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cameron MD, et al.  Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer Res. 2000;60:2541–2546.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10811137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kienast Y, et al.  Real-time imaging reveals the single steps of brain metastasis formation. Nat Med. 2010;16:116–122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20023634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valiente M, et al.  Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell. 2014;156:1002–1016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3988473</ArticleId>
            <ArticleId IdType="pubmed">24581498</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heyn C, et al.  In vivo MRI of cancer cell fate at the single-cell level in a mouse model of breast cancer metastasis to the brain. Magn Reson Med. 2006;56:1001–1010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17029229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malanchi I, et al.  Interactions between cancer stem cells and their niche govern metastatic colonization. Nature. 2012;481:85–89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22158103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calon A, et al.  Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell. 2012;22:571–584.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3512565</ArticleId>
            <ArticleId IdType="pubmed">23153532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9:274–284.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19308067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331:1559–1564.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21436443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hall A. The cytoskeleton and cancer. Cancer Metastasis Rev. 2009;28:5–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19153674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141:52–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2862057</ArticleId>
            <ArticleId IdType="pubmed">20371345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423–1437.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3954707</ArticleId>
            <ArticleId IdType="pubmed">24202395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giampieri S, et al.  Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol. 2009;11:1287–1296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2773241</ArticleId>
            <ArticleId IdType="pubmed">19838175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roh-Johnson M, et al.  Macrophage contact induces RhoA GTPase signaling to trigger tumor cell intravasation. Oncogene. 2014;33:4203–4212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3962803</ArticleId>
            <ArticleId IdType="pubmed">24056963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedl P, Gilmour D. Collective cell migration in morphogenesis, regeneration and cancer. Nat Rev Mol Cell Biol. 2009;10:445–457.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19546857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magnon C, et al.  Autonomic nerve development contributes to prostate cancer progression. Science. 2013;341:1236361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23846904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871–890.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19945376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tam WL, Weinberg RA. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med. 2013;19:1438–1449.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4190672</ArticleId>
            <ArticleId IdType="pubmed">24202396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer KR, et al.  EMT is not required for lung metastasis but contributes to chemoresistance. Nature.  in press.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4662610</ArticleId>
            <ArticleId IdType="pubmed">26560033</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng X, et al.  Epithelial to Mesenchymal Transition is dispensable for metastasis but confers chemoresistance in pancreatic cancer. Nature.  in press.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4849281</ArticleId>
            <ArticleId IdType="pubmed">26560028</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tabassum DP, Polyak K. Tumorigenesis: it takes a village. Nat Rev Cancer. 2015;15:473–483.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26156638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marusyk A, et al.  Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature. 2014;514:54–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4184961</ArticleId>
            <ArticleId IdType="pubmed">25079331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cleary AS, Leonard TL, Gestl SA, Gunther EJ. Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers. Nature. 2014;508:113–117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4050741</ArticleId>
            <ArticleId IdType="pubmed">24695311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calbo J, et al.  A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. Cancer Cell. 2011;19:244–256.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21316603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gundem G, et al.  The evolutionary history of lethal metastatic prostate cancer. Nature. 2015;520:353–357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4413032</ArticleId>
            <ArticleId IdType="pubmed">25830880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aceto N, et al.  Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014;158:1110–1122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4149753</ArticleId>
            <ArticleId IdType="pubmed">25171411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20:576–590.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3487108</ArticleId>
            <ArticleId IdType="pubmed">22094253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le Gal K, et al.  Antioxidants can increase melanoma metastasis in mice. Sci Transl Med. 2015;7:308re308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26446958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piskounova E, et al.  Oxidative stress inhibits distant metastasis by human melanoma cells. Nature. 2015</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4644103</ArticleId>
            <ArticleId IdType="pubmed">26466563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deneve E, et al.  Capture of viable circulating tumor cells in the liver of colorectal cancer patients. Clin Chem. 2013;59:1384–1392.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23695297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Mehdi AB, et al.  Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat Med. 2000;6:100–102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10613833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aird WC. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res. 2007;100:158–173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17272818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Budczies J, et al.  The landscape of metastatic progression patterns across major human cancers. Oncotarget. 2015;6:570–583.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4381616</ArticleId>
            <ArticleId IdType="pubmed">25402435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Minn AJ, et al.  Genes that mediate breast cancer metastasis to lung. Nature. 2005;436:518–524.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1283098</ArticleId>
            <ArticleId IdType="pubmed">16049480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsuda Y, Schlange T, Oakeley EJ, Boulay A, Hynes NE. WNT signaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth. Breast Cancer Res. 2009;11:R32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2716500</ArticleId>
            <ArticleId IdType="pubmed">19473496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Padua D, et al.  TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell. 2008;133:66–77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2390892</ArticleId>
            <ArticleId IdType="pubmed">18394990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta GP, et al.  Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature. 2007;446:765–770.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17429393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tichet M, et al.  Tumour-derived SPARC drives vascular permeability and extravasation through endothelial VCAM1 signalling to promote metastasis. Nat Commun. 2015;6:6993.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25925867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weis S, Cui J, Barnes L, Cheresh D. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol. 2004;167:223–229.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2172541</ArticleId>
            <ArticleId IdType="pubmed">15504909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schumacher D, Strilic B, Sivaraj KK, Wettschureck N, Offermanns S. Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell. 2013;24:130–137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23810565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qian BZ, et al.  CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475:222–225.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3208506</ArticleId>
            <ArticleId IdType="pubmed">21654748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bos PD, et al.  Genes that mediate breast cancer metastasis to the brain. Nature. 2009;459:1005–1009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2698953</ArticleId>
            <ArticleId IdType="pubmed">19421193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sevenich L, et al.  Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S. Nat Cell Biol. 2014;16:876–888.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4249762</ArticleId>
            <ArticleId IdType="pubmed">25086747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou W, et al.  Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell. 2014;25:501–515.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4016197</ArticleId>
            <ArticleId IdType="pubmed">24735924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tominaga N, et al.  Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier. Nat Commun. 2015;6:6716.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4396394</ArticleId>
            <ArticleId IdType="pubmed">25828099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21:309–322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22439926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003;3:453–458.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12778135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim MY, et al.  Tumor self-seeding by circulating cancer cells. Cell. 2009;139:1315–1326.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2810531</ArticleId>
            <ArticleId IdType="pubmed">20064377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Obenauf AC, et al.  Therapy-induced tumour secretomes promote resistance and tumour progression. Nature. 2015;520:368–372.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4507807</ArticleId>
            <ArticleId IdType="pubmed">25807485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eyles J, et al.  Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest. 2010;120:2030–2039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2877955</ArticleId>
            <ArticleId IdType="pubmed">20501944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bidwell BN, et al.  Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med. 2012;18:1224–1231.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22820642</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smyth MJ, et al.  Perforin is a major contributor to NK cell control of tumor metastasis. J Immunol. 1999;162:6658–6662.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10352283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paolino M, et al.  The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature. 2014;507:508–512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6258903</ArticleId>
            <ArticleId IdType="pubmed">24553136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Milsom CC, Lee CR, Hackl C, Man S, Kerbel RS. Differential post-surgical metastasis and survival in SCID, NOD-SCID and NOD-SCID-IL-2Rgamma(null) mice with parental and subline variants of human breast cancer: implications for host defense mechanisms regulating metastasis. PLoS One. 2013;8:e71270.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3743873</ArticleId>
            <ArticleId IdType="pubmed">23967178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takeda K, et al.  Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med. 2001;7:94–100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11135622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Postow MA, et al.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006–2017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5744258</ArticleId>
            <ArticleId IdType="pubmed">25891304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161:205–214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5905674</ArticleId>
            <ArticleId IdType="pubmed">25860605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morrison SJ, Spradling AC. Stem cells and niches: mechanisms that promote stem cell maintenance throughout life. Cell. 2008;132:598–611.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4505728</ArticleId>
            <ArticleId IdType="pubmed">18295578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsu YC, Li L, Fuchs E. Emerging interactions between skin stem cells and their niches. Nat Med. 2014;20:847–856.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4358898</ArticleId>
            <ArticleId IdType="pubmed">25100530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schepers AG, et al.  Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science. 2012;337:730–735.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22855427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen J, et al.  A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 2012;488:522–526.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3427400</ArticleId>
            <ArticleId IdType="pubmed">22854781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Driessens G, Beck B, Caauwe A, Simons BD, Blanpain C. Defining the mode of tumour growth by clonal analysis. Nature. 2012;488:527–530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5553110</ArticleId>
            <ArticleId IdType="pubmed">22854777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell. 2014;14:275–291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24607403</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oskarsson T, Batlle E, Massague J. Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell. 2014;14:306–321.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3998185</ArticleId>
            <ArticleId IdType="pubmed">24607405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shiozawa Y, et al.  Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest. 2011;121:1298–1312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3069764</ArticleId>
            <ArticleId IdType="pubmed">21436587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muller A, et al.  Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11242036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang XH, et al.  Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma. Cell. 2013;154:1060–1073.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3974915</ArticleId>
            <ArticleId IdType="pubmed">23993096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hambardzumyan D, et al.  PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev. 2008;22:436–448.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2238666</ArticleId>
            <ArticleId IdType="pubmed">18281460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao Z, et al.  Angiocrine factors deployed by tumor vascular niche induce B cell lymphoma invasiveness and chemoresistance. Cancer Cell. 2014;25:350–365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4017921</ArticleId>
            <ArticleId IdType="pubmed">24651014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carbonell WS, Ansorge O, Sibson N, Muschel R. The vascular basement membrane as"soil" in brain metastasis. PLoS One. 2009;4:e5857.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2689678</ArticleId>
            <ArticleId IdType="pubmed">19516901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oskarsson T, et al.  Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med. 2011;17:867–874.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4020577</ArticleId>
            <ArticleId IdType="pubmed">21706029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Erler JT, et al.  Lysyl oxidase is essential for hypoxia-induced metastasis. Nature. 2006;440:1222–1226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16642001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gilkes DM, et al.  Procollagen lysyl hydroxylase 2 is essential for hypoxia-induced breast cancer metastasis. Mol Cancer Res. 2013;11:456–466.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3656974</ArticleId>
            <ArticleId IdType="pubmed">23378577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eisinger-Mathason TS, et al.  Hypoxia-dependent modification of collagen networks promotes sarcoma metastasis. Cancer Discov. 2013;3:1190–1205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3822914</ArticleId>
            <ArticleId IdType="pubmed">23906982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaplan RN, et al.  VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438:820–827.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2945882</ArticleId>
            <ArticleId IdType="pubmed">16341007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McAllister SS, Weinberg RA. The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol. 2014;16:717–727.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6220424</ArticleId>
            <ArticleId IdType="pubmed">25082194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cox TR, et al.  The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature. 2015;522:106–110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4961239</ArticleId>
            <ArticleId IdType="pubmed">26017313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costa-Silva B, et al.  Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol. 2015;17:816–826.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5769922</ArticleId>
            <ArticleId IdType="pubmed">25985394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Erler JT, et al.  Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell. 2009;15:35–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3050620</ArticleId>
            <ArticleId IdType="pubmed">19111879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wculek SK, Malanchi I. Pre-metastatic neutrophils support highly lung metastatic breast cancer cells. Nature.  in press.</Citation>
        </Reference>
        <Reference>
          <Citation>Peinado H, et al.  Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012;18:883–891.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3645291</ArticleId>
            <ArticleId IdType="pubmed">22635005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoshino A, et al.  Tumour exosome integrins determine organotropic metastasis. Nature.  in press.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4788391</ArticleId>
            <ArticleId IdType="pubmed">26524530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nowak DG, et al.  MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2. Cancer Discov. 2015;5:636–651.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4456272</ArticleId>
            <ArticleId IdType="pubmed">25829425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li B, et al.  Id1-induced IGF-II and its autocrine/endocrine promotion of esophageal cancer progression and chemoresistance--implications for IGF-II and IGF-IR-targeted therapy. Clin Cancer Res. 2014;20:2651–2662.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24599933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang XH, et al.  Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell. 2009;16:67–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2749247</ArticleId>
            <ArticleId IdType="pubmed">19573813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wyckoff J, et al.  A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res. 2004;64:7022–7029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15466195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Acharyya S, et al.  A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell. 2012;150:165–178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3528019</ArticleId>
            <ArticleId IdType="pubmed">22770218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tabaries S, et al.  Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytes. Mol Cell Biol. 2012;32:2979–2991.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3434516</ArticleId>
            <ArticleId IdType="pubmed">22645303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Q, Zhang XH, Massague J. Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell. 2011;20:538–549.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3293160</ArticleId>
            <ArticleId IdType="pubmed">22014578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu X, et al.  VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell. 2011;20:701–714.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3241854</ArticleId>
            <ArticleId IdType="pubmed">22137794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vanharanta S, et al.  Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. Nat Med. 2013;19:50–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3540187</ArticleId>
            <ArticleId IdType="pubmed">23223005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tavazoie SF, et al.  Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008;451:147–152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2782491</ArticleId>
            <ArticleId IdType="pubmed">18185580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449:682–688.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17898713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Korpal M, et al.  Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med. 2011;17:1101–1108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3169707</ArticleId>
            <ArticleId IdType="pubmed">21822286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pencheva N, et al.  Convergent multi-miRNA targeting of ApoE drives LRP1/LRP8-dependent melanoma metastasis and angiogenesis. Cell. 2012;151:1068–1082.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3753115</ArticleId>
            <ArticleId IdType="pubmed">23142051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer. 2004;4:448–456.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15170447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sosa MS, Bragado P, Aguirre-Ghiso JA. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer. 2014;14:611–622.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4230700</ArticleId>
            <ArticleId IdType="pubmed">25118602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang Y, Pantel K. Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell. 2013;23:573–581.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3667710</ArticleId>
            <ArticleId IdType="pubmed">23680145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao H, et al.  The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell. 2012;150:764–779.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3711709</ArticleId>
            <ArticleId IdType="pubmed">22901808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bragado P, et al.  TGF-beta2 dictates disseminated tumour cell fate in target organs through TGF-beta-RIII and p38alpha/beta signalling. Nat Cell Biol. 2013;15:1351–1361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4006312</ArticleId>
            <ArticleId IdType="pubmed">24161934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kobayashi A, et al.  Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J Exp Med. 2011;208:2641–2655.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3244043</ArticleId>
            <ArticleId IdType="pubmed">22124112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghajar CM, et al.  The perivascular niche regulates breast tumour dormancy. Nat Cell Biol. 2013;15:807–817.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3826912</ArticleId>
            <ArticleId IdType="pubmed">23728425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barkan D, et al.  Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment. Cancer Res. 2010;70:5706–5716.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3436125</ArticleId>
            <ArticleId IdType="pubmed">20570886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aguirre-Ghiso JA, Liu D, Mignatti A, Kovalski K, Ossowski L. Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell. 2001;12:863–879.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC32272</ArticleId>
            <ArticleId IdType="pubmed">11294892</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strauss DC, Thomas JM. Transmission of donor melanoma by organ transplantation. Lancet Oncol. 2010;11:790–796.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20451456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collignon FP, Holland EC, Feng S. Organ donors with malignant gliomas: an update. Am J Transplant. 2004;4:15–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14678030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Obenauf AC, Massague J. Surviving at a distance: Organ specific metastasis. Trends Cancer. 2015;1:76–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4673677</ArticleId>
            <ArticleId IdType="pubmed">28741564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Urosevic J, et al.  Colon cancer cells colonize the lung from established liver metastases through p38 MAPK signalling and PTHLH. Nat Cell Biol. 2014;16:685–694.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24880666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer. 2011;11:411–425.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3666847</ArticleId>
            <ArticleId IdType="pubmed">21593787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin JJ, et al.  TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest. 1999;103:197–206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC407876</ArticleId>
            <ArticleId IdType="pubmed">9916131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang Y, et al.  A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003;3:537–549.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12842083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lynch CC, et al.  MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell. 2005;7:485–496.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15894268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu X, et al.  ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev. 2009;23:1882–1894.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2725946</ArticleId>
            <ArticleId IdType="pubmed">19608765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sethi N, Dai X, Winter CG, Kang Y. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell. 2011;19:192–205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3040415</ArticleId>
            <ArticleId IdType="pubmed">21295524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ell B, et al.  Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. Cancer Cell. 2013;24:542–556.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3832956</ArticleId>
            <ArticleId IdType="pubmed">24135284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim SW, et al.  Role of the endothelin axis in astrocyte- and endothelial cell-mediated chemoprotection of cancer cells. Neuro Oncol. 2014;16:1585–1598.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4232084</ArticleId>
            <ArticleId IdType="pubmed">25008093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Early Breast Cancer Trialists' Collaborative G, et al.  Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015;386:1353–1361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26211824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gnant M, et al.  Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;386:433–443.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26040499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13:714–726.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24060863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Higgins MJ, Baselga J. Targeted therapies for breast cancer. J Clin Invest. 2011;121:3797–3803.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3195649</ArticleId>
            <ArticleId IdType="pubmed">21965336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lito P, et al.  Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell. 2012;22:668–682.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3713778</ArticleId>
            <ArticleId IdType="pubmed">23153539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gilbert LA, Hemann MT. DNA damage-mediated induction of a chemoresistant niche. Cell. 2010;143:355–366.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2972353</ArticleId>
            <ArticleId IdType="pubmed">21029859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun Y, et al.  Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med. 2012;18:1359-+.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3677971</ArticleId>
            <ArticleId IdType="pubmed">22863786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith MP, et al.  The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFalpha. Cancer Discov. 2014;4:1214–1229.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4184867</ArticleId>
            <ArticleId IdType="pubmed">25256614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang T, et al.  BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. Clin Cancer Res. 2015;21:1652–1664.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4383683</ArticleId>
            <ArticleId IdType="pubmed">25617424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Straussman R, et al.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487:500–504.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3711467</ArticleId>
            <ArticleId IdType="pubmed">22763439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kurtova AV, et al.  Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature. 2015;517:209–213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4465385</ArticleId>
            <ArticleId IdType="pubmed">25470039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang Q, et al.  Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med. 2011;17:860–866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3132290</ArticleId>
            <ArticleId IdType="pubmed">21725296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Macosko EZ, et al.  Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets. Cell. 2015;161:1202–1214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4481139</ArticleId>
            <ArticleId IdType="pubmed">26000488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patel AP, et al.  Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014;344:1396–1401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4123637</ArticleId>
            <ArticleId IdType="pubmed">24925914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levine JH, et al.  Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis. Cell. 2015;162:184–197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4508757</ArticleId>
            <ArticleId IdType="pubmed">26095251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lawson DA, et al.  Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature. 2015;526:131–135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4648562</ArticleId>
            <ArticleId IdType="pubmed">26416748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481:306–313.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3367003</ArticleId>
            <ArticleId IdType="pubmed">22258609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vanharanta S, Massague J. Origins of metastatic traits. Cancer Cell. 2013;24:410–421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3998120</ArticleId>
            <ArticleId IdType="pubmed">24135279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naxerova K, Jain RK. Using tumour phylogenetics to identify the roots of metastasis in humans. Nat Rev Clin Oncol. 2015;12:258–272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25601447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Campbell PJ, et al.  The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 2010;467:1109–1113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3137369</ArticleId>
            <ArticleId IdType="pubmed">20981101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robinson D, et al.  Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215–1228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4484602</ArticleId>
            <ArticleId IdType="pubmed">26000489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pencheva N, Tavazoie SF. Control of metastatic progression by microRNA regulatory networks. Nat Cell Biol. 2013;15:546–554.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4678324</ArticleId>
            <ArticleId IdType="pubmed">23728460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer. 2009;9:302–312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19308069</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
